3 results
Approved WMOCompleted
To estimate the bleeding risk with rivaroxaban, compared with ASA, in addition to a singleantiplatelet agent (clopidogrel or ticagrelor), in subjects with a recent ACS .
Approved WMORecruiting
First: to determine the technical and logistical feasibility of measuring changes in myocardial perfusion and left ventricular function with gated 13N-NH3 PET before and during HD. Second: to compare changes in myocardial perfusion and left…
Approved WMOWill not start
To assess the safety and tolerability of ascending doses of PP-001 whenadministered as a single intravitreal injection from 0,3 *g, 0,6 *g and 1,2*g with the option of an addition cohort with a dose of 2,1 *g PP-001.To assess the efficacy of…